NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with drug maker Bristol-Myers Squibb to develop clinical diagnostics as companions to cancer therapeutics.
 
The Danish diagnostics firm plans to develop clinical diagnostics that can identify cancer patients who may benefit from drug candidates that Bristol-Myers Squibb has in development.
 
Dako CEO Patrick Dahlen said the tests it develops under the collaboration will be companion products for specific Bristol-Myers Squibb therapeutics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.